Medtronic (NYSE:MDT) today said it won FDA clearance for its cranial robotic platform the Stealth Autoguide system.
The Stealth Autoguide Platform is a robotic guidance system that is designed for spatial positioning and orientation of instrument holders and tool guides that are used in neurosurgical procedures.
“Medtronic continues to deliver on its commitment of developing innovative technologies that helps physicians seamlessly provide high-quality care for cranial and other procedures,” David Adelson, division chief of neurosurgery and director of Barrow Neurological Institute at Phoenix Children’s Hospital, said in a news release. “The precision provided by the Stealth Autoguide system will help my clinical team accomplish unique surgical scenarios with increased accuracy.”
Medtronic’s Stealth Autoguide Platform is cleared for use in biopsy procedures, stereoelectroencephalography (sEEG) depth electrode placement and for positioning the Visualase bone anchor in catheter placement.
“The Stealth Autoguide Platform provides surgeons and operating room staff with robotic-assisted positioning and trajectory guidance for cranial procedures confirming consistent, repeatable and accurate alignment to their surgical plans,” VP and GM of enabling technologies at Medtronic Dave Anderson said. “The Stealth Autoguide Platform showcases Medtronic’s commitment to advancing care and delivering the best outcomes to the most patients possible through our Surgical Synergy platform.”
